Payment overview · 2025
General Payments
$759.46
43 reported records · 14 companies
Healthcare provider profile · identity verified
Danilo Agustin Dona, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NEWPORT, MI · NPI 1922024637
Verified facts
What the public records show
CMS Open Payments records show Danilo Agustin Dona, M.D. received $759.46 in general payments during 2025 across 43 reported records.
HARMONY BIOSCIENCES LLC accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $191.83 | 25.3% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $174.14 | 22.9% | 12 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.46 | 10.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $63.48 | 8.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.63 | 7.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $54.99 | 7.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.87 | 4.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.09 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.09 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.96 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.17 | 2.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.74 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.46 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.55 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $712.47 | 42 |
| Education | $46.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $174.14 | 12 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $144.84 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $77.46 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $63.48 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $54.99 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.01 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
88 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 103 |
| Omeprazole | Omeprazole | 257 | 87 |
| Metformin Hcl | Metformin Hcl | 255 | 78 |
| Fluticasone Propionate | Fluticasone Propionate | 237 | 121 |
| Lisinopril | Lisinopril | 224 | 68 |
| Gabapentin | Gabapentin | 214 | 57 |
| Losartan Potassium | Losartan Potassium | 211 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 201 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 197 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 73 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 187 | 129 |
| Prednisone | Prednisone | 181 | 100 |
| Alprazolam | Alprazolam | 154 | 40 |
| Methylprednisolone | Methylprednisolone | 138 | 100 |
| Ibuprofen | Ibuprofen | 136 | 47 |
| Trazodone Hcl | Trazodone Hcl | 131 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 46 |
| Furosemide | Furosemide | 123 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 121 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 33 |
| Potassium Chloride | Potassium Chloride | 99 | 42 |
| Fenofibrate | Fenofibrate Nanocrystallized | 98 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 97 | 39 |
| Montelukast Sodium | Montelukast Sodium | 97 | 40 |
| Pregabalin | Pregabalin | 97 | 24 |
| Glipizide | Glipizide | 93 | 28 |
| Carvedilol | Carvedilol | 92 | 26 |
| Jardiance | Empagliflozin | 90 | 23 |
| Nifedipine Er | Nifedipine | 89 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 88 | 30 |
| Ozempic | Semaglutide | 83 | 19 |
| Clindamycin Hcl | Clindamycin Hcl | 78 | 52 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 76 | 54 |
| Buspirone Hcl | Buspirone Hcl | 75 | 21 |
| Cephalexin | Cephalexin | 74 | 36 |
| Meloxicam | Meloxicam | 74 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 25 |
| Sertraline Hcl | Sertraline Hcl | 69 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | 32 |
| Eliquis | Apixaban | 68 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 44 |
| Atenolol | Atenolol | 60 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 60 | 19 |
| Januvia | Sitagliptin Phosphate | 57 | 19 |
| Simvastatin | Simvastatin | 54 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 16 |
| Tramadol Hcl | Tramadol Hcl | 48 | 25 |
| Allopurinol | Allopurinol | 46 | 15 |
| Spironolactone | Spironolactone | 46 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 40 | 31 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 12 |
| Fluconazole | Fluconazole | 36 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 13 |
| Ezetimibe | Ezetimibe | 35 | 12 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 13 |
| Primidone | Primidone | 30 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 26 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 24 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | 11 |
| Finasteride | Finasteride | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 13 |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $759.46 · 43 records | HARMONY BIOSCIENCES LLC | AIRSUPRA, AREXVY, Auvelity, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, OTEZLA, Ozempic, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, WAKIX, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error